You just read:

Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Jun 26, 2010, 10:00 ET